Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.

about

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

P2860

Q58603002-EC2D6840-FC25-4E66-9B87-E15CC3B6C242

P2860

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.

Item

http://www.wikidata.org/entity/Q47890627

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Real-world visual outcomes in ...... d intervals as per UK licence.

@en

Real-world visual outcomes in ...... d intervals as per UK licence.

@nl

type

Item

label

Real-world visual outcomes in ...... d intervals as per UK licence.

@en

Real-world visual outcomes in ...... d intervals as per UK licence.

@nl

prefLabel

Real-world visual outcomes in ...... d intervals as per UK licence.

@en

Real-world visual outcomes in ...... d intervals as per UK licence.

@nl

P1476

Real-world visual outcomes in ...... d intervals as per UK licence.

@en

P2093

Daniel Barthelmes

http://www.w3.org/2001/XMLSchema#string

Hemal Mehta

http://www.w3.org/2001/XMLSchema#string

Mark C Gillies

http://www.w3.org/2001/XMLSchema#string

Martin L Harris

http://www.w3.org/2001/XMLSchema#string

Mehmet Ozturk

http://www.w3.org/2001/XMLSchema#string

P2860

Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project.

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.

UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.

TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome.

First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.

Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

P31

scholarly article

P356

10.1111/CEO.13085

http://www.w3.org/2001/XMLSchema#string

P50

Vuong Nguyen

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29044979

http://www.w3.org/2001/XMLSchema#string

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.

about

P2860

P2860

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698